url:https://finance.yahoo.com/m/d56f4fe4-7170-3ed3-9e90-cfa9a6ca231d/why-crispr-therapeutics-stock.html
title:Why_CRISPR_Therapeutics_Stock_Could_Be_About_to_Take_Off
CRISPR Therapeutics (NASDAQ: CRSP) is a company that doesn't have an approved product on the market. There are many reasons that this may look like a risky, dangerous stock to own. The big news for CRISPR is whether the Food and Drug Administration (FDA) will approve the gene-editing therapy exa-cel that it has been developing with Vertex Pharmaceuticals.